{
  "id": 10790210,
  "title": "#EASD26: Zealand and Roche's amylin works best at middle dose, trails Lilly's",
  "url": "https://urgent.news/2026/09/29/easd26-zealand-and-roches-amylin-works-best-at-middle-dose-trails",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-29T22:01:52.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/easd26-zealand-roches-amylin-works-best-at-middle-dose-but-still-trails-lillys/"
  },
  "original_language": "en",
  "account": null,
  "summary": "MILAN — Weight loss with Zealand and Roche’s amylin analog was regarded as disappointing when its Phase 2 obesity trial reported topline data in March. Fuller data unveiled at a conference on Tuesday ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "#EASD26: Lilly's triple-G allows 60% of patients to drop below obesity threshold",
        "url": "https://urgent.news/2026/09/29/easd26-lillys-triple-g-allows-60-of-patients-to-drop-below-obesity",
        "published": "2026-09-29T22:01:10.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}